Proteasome inhibibor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. by Paniagua, Soriano G. et al.
OPEN
ORIGINAL ARTICLE
Proteasome inhibitor-adapted myeloma cells are largely
independent from proteasome activity and show complex
proteomic changes, in particular in redox and energy
metabolism
GP Soriano1,4, L Besse2,4, N Li1, M Kraus2, A Besse2, N Meeuwenoord1, J Bader2, B Everts3, H den Dulk1, HS Overkleeft1, BI Florea1
and C Driessen2
Adaptive resistance of myeloma to proteasome inhibition represents a clinical challenge, whose biology is poorly understood.
Proteasome mutations were implicated as underlying mechanism, while an alternative hypothesis based on low activation status of
the unfolded protein response was recently suggested (IRE1/XBP1-low model). We generated bortezomib- and carﬁlzomib-adapted,
highly resistant multiple myeloma cell clones (AMO-BTZ, AMO-CFZ), which we analyzed in a combined quantitative and functional
proteomic approach. We demonstrate that proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition,
irrespective of a proteasome mutation, and uniformly show an 'IRE1/XBP1-low' signature. Adaptation of myeloma cells to
proteasome inhibitors involved quantitative changes in4600 protein species with similar patterns in AMO-BTZ and AMO-CFZ cells:
proteins involved in metabolic regulation, redox homeostasis, and protein folding and destruction were upregulated, while
apoptosis and transcription/translation were downregulated. The quantitatively most upregulated protein in AMO-CFZ cells was the
multidrug resistance protein (MDR1) protein ABCB1, and carﬁlzomib resistance could be overcome by MDR1 inhibition. We propose
a model where proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition owing to metabolic
adaptations that favor the generation of reducing equivalents, such as NADPH, which is supported by oxidative glycolysis.
Proteasome inhibitor resistance may thus be targeted by manipulating the energy and redox metabolism.
Leukemia (2016) 30, 2198–2207; doi:10.1038/leu.2016.102
INTRODUCTION
Proteasome inhibition is highly active for the treatment of
multiple myeloma (MM).1 Current proteasome-inhibiting drugs
comprise the ﬁrst-in-class, reversible, boronate-type proteasome
inhibitor bortezomib and its oral permutation ixazomib and the
approved, irreversible, epoxyketone-type inhibitor carﬁlzomib, as
well as next-generation boronate-, epoxyketone- or β-lactone-type
of inhibitors.2 Their mechanism of action exploits the highly
developed protein biosynthesis machinery of myeloma.3 This
extraordinarily active biosynthetic route is controlled by the
unfolded protein response (UPR), a complex transcriptional
network that balances protein transcription, folding and
destruction.4 The IRE1/XBP1 pathway, one of the three key
regulatory switches to control UPR activity, also guides plasma cell
differentiation.5,6 MM cells critically rely on timely disposal of
misfolded and dysfunctional newly synthesized protein through
the endoplasmic reticulum (ER)-associated degradation machin-
ery, of which the proteasome is the rate limiting protease.7
Functional proteasome inhibition disrupts the equilibrium
between production and disposal of such protein, which leads
to proteotoxic stress and excess activation of the UPR, triggering
apoptosis.3
The constitutive proteasome is composed of three pairs of
proteolytically active sites (β1c, β2c, β5c) with different substrate
speciﬁcity.8 Immune cells, including myeloma, may replace
these by respective active sites of the immunoproteasome (β1i,
β2i, β5i).9,10 The β5 activity is rate-limiting, and consequently
bortezomib and carﬁlzomib, as well as all synthetic proteasome
inhibitors in clinical development, are designed to target β5.2,11–13
Proteasome inhibitor resistance of MM is an emerging clinical
problem whose biology is poorly understood. Proteasome
inhibitor-resistant cell lines generated in vitro by continuous
exposure to proteasome-inhibiting drugs serve as models to
understand and potentially overcome proteasome inhibitor
resistance.14–16 Mutations in PSMB5 (encoding for β5c) were
predicted to lead to impaired inhibitor binding owing to changes
in the β5c active site or the inhibitor-binding pocket.14,17,18
However, the functional relevance of such mutations on the active
site binding of bortezomib or carﬁlzomib in MM cells has not been
demonstrated, and extensive analysis in MM cells derived from
patients resistant to proteasome inhibitor therapy failed to
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identify such PSMB5 mutations.19 Moreover, artiﬁcial introduction
of mutant PSMB5 in MM cells did not confer bortezomib resistance
comparable to bortezomib-selected tumor cells.20 Recently, an
alternative biological model for proteasome inhibitor resistance
was put forward, supported by respective ﬁndings from MM cells
of bortezomib-resistant patients. It suggests that bortezomib
resistance is the result of changes in the activation status of the
UPR, in particular decreased activity of the IRE1/XBP1 axis,21
consistent with high XBP1 being a biomarker for bortezomib
sensitivity in the clinic.22
We here dissect the relationship between PSMB5 mutation,
proteasome inhibitor target inhibition and resistance to protea-
some inhibitor-induced cell death of MM cells. Because our results
suggest a complex mechanism of proteasome inhibitor resistance
largely independent from either PSMB5 mutations or even
signiﬁcant β5c proteasome activity, we provide a global proteomic
comparison of proteasome inhibitor-sensitive vs bortezomib- and
carﬁlzomib-adapted myeloma cells to identify novel potential
therapeutic strategies beyond the ubiquitin proteasome pathway.
METHODS
Cell culture
The AMO-1 proteasome inhibitor-resistant cell lines (AMO-BTZ and AMO-
CFZ) as well as their single clone-derived derivatives were established and
maintained from the AMO-1 myeloma cell line by continuous drug
exposure for 412 months.15 Additional information is provided in
Supplementary Methods.
Relationship between proteasome inhibition and cytotoxicity
Measurement of proteasome activity was performed as described
previously.23 Additional information is provided in Supplementary
Methods.
Proteome analysis
Brieﬂy, full-cell lysates were digested with trypsin labeled with light (sensitive
cells AMO-1) or intermediate (adapted cells) stable formaldehyde isotopes,24
mixed, fractionated by SCX and analyzed by liquid chromatography-tandem
mass spectrometry. Each analysis was performed in triplicate. The MaxQuant
(Max Planck Institute of Biochemistry, Martinsried, Germany) was used for
identiﬁcation and quantiﬁcation of the proteins. A cutoff of log2= 0.5 was
chosen to categorize differentially expressed proteins. The differentially
expressed proteins were subjected to a protein–protein interaction analysis
with the Cytoscape (The Cytoscape Consortium, San Diego, CA, USA). Gene
ontology (GO) analysis was performed with the BinGo (The Cytoscape
Consortium).25 Manual curation was carried out to cluster the GO terms in
more general groups (see Supplementary Materials for full protocol).
Statistical analysis
If not stated otherwise, results represent means and s.d. from at least
three independent experiments. Additional information is provided in
Supplementary Methods.
RESULTS
Subtotal functional proteasome inhibition lacks cytotoxicity in
proteasome inhibitor-adapted myeloma cells
Sequencing of the active subunits of the constitutive proteasome
revealed a heterozygous A310G mutation leading to a Met45Val
change in the S1 pocket of the PSMB5 active site in AMO-BTZ
bulk cultures as well as in all single cell-derived clones from
these cultures (data not shown). Genetic changes in the PSMB5
(β5c) PSMB6 (β1c) and PSMB7 (β2c) genes could be excluded in
AMO-CFZ cells. Therefore, all experiments with AMO-BTZ cells
reported here were performed with the Met45Val mutation
present, while all experiments in AMO-CFZ were performed in
the absence of a mutation. The IC50 for β5c during bortezomib
treatment was higher in AMO-BTZ, compared with AMO-1 and
AMO-CFZ, while the IC50 for β1c was comparable (Figure 1a;
Table 1). Bortezomib increased β2 activity in AMO-1 cells but not
in AMO-BTZ or AMO-CFZ. Treatment with 250 nM bortezomib, a
concentration in the range of peak bortezomib plasma levels in
myeloma patients minutes after intravenous bolus administration,
induced approximately 70–80% inhibition of active β5c in AMO-1,
AMO-BTZ or AMO-CFZ cells. This resulted in490% cytotoxicity in
AMO-1 cells, while viability in AMO-BTZ or AMO-CFZ remained
490%. Apoptosis was conﬁrmed by propidium iodide/Annexin
V staining (Supplementary Figure S1). HL60 acute myeloid
leukemia cells similarly adapted to bortezomib (HL60-BTZ) and
lacking a PSMB5 mutation showed not only similarly effective
proteasome β5c/β5i inhibition by bortezomib, compared with
non-adapted control cells, but also a lower sensitivity to
bortezomib-induced cytotoxicity (data not shown).
Carﬁlzomib was more selective for β5c/5i activity over β1c/1i
activity and, in addition, had some β2c/2i-inhibiting activity, both
in contrast to bortezomib (Figure 1b; Table 1, Supplementary
Figure S2). The IC50 values of β2c/2i and β1c/1i were in the same
order of magnitude for carﬁlzomib treatment in AMO-1 and AMO-
BTZ. By contrast, the IC50 for β5c was approximately ﬁve-fold
lower in AMO-1 vs AMO-BTZ cells (10 vs 50 nM), suggesting that
the PSMB5 A310G mutation also affects β5 binding of carﬁlzomib,
comparable to bortezomib. Inhibition of β5c by carﬁlzomib was
9 × less effective in AMO-CFZ, compared with AMO-1, while this
difference had a factor of only two for bortezomib. Likewise,
inhibition of β1/β1i and β2/β2i by carﬁlzomib was less effective in
AMO-CFZ than in AMO-1. When approximately equally effective
proteasome inhibition was achieved by carﬁlzomib in AMO-1,
AMO-BTZ and AMO-CFZ (490% inhibition of β5c/5i, 20%
inhibition of β1/1i and β2/2i, achieved by 250 nM carﬁlzomib in
AMO-1 and AMO-BTZ, and 1000 nM carﬁlzomib in AMO-CFZ), this
resulted in460% cytotoxicity in AMO-1 cells, in contrast to AMO-
BTZ or AMO-CFZ.
Proteasome inhibitor-adapted myeloma cells show low IRE1/XBP1
expression
Protein and mRNA expression for IRE1 was uniformly decreased in
AMO-BTZ and AMO-CFZ, (Figure 2). Consistent with this, spliced
XBP1 was reduced on the mRNA and protein level, while total
XBP1 and unspliced XBP1 were increased. Thus AMO-BTZ and
AMO-CFZ both match the 'IRE1/sXBP1-low' expression pattern that
was observed in myeloma cells from bortezomib-refractory
patients. We did not ﬁnd changes in the expression of protein
or mRNA indicative of an activation of autophagy in AMO-BTZ or
AMO-CFZ (Supplementary Figure S3).
We compared the effects of equi-efﬁcient proteasome inhibi-
tion on the activation of the UPR-induced apoptotic machinery
(Figure 3). AMO-1, AMO-BTZ and AMO-CFZ cells were pulse-
treated for 1 h with bortezomib, followed by western blotting
analysis of UPR-related proteins. Loss of expression of the active
version of the NRF1 transcription factor that is generated by
partial proteolysis through the proteasome26 conﬁrmed functional
proteasome inhibition for 8 h in all treated cells, independent from
the PSMB5 mutation status. Phosphorylation of IRE1 and expres-
sion of spliced XBP1 was triggered within 1–2 h upon bortezomib
challenge in all cell lines, and increased expression of PKR-like ER
kinase was initiated at later time points. Triggering of the UPR-
associated apoptotic machinery was observed in all cells, based on
the expression of ATF4 and CHOP and activation of caspase 3,
albeit with lower signal intensity in AMO-BTZ. By contrast, protein
disulﬁde isomerase (PDI), a key enzyme for the formation of
disulﬁde bonds and protein folding in the ER, showed low
expression in AMO-1 at baseline and was strongly induced by
bortezomib, while it was constitutively expressed at considerably
higher levels in AMO-BTZ or AMO-CFZ cells without signiﬁcant
The proteome of proteasome inhibitor-resistant myeloma
GP Soriano et al
2199
© 2016 Macmillan Publishers Limited, part of Springer Nature. Leukemia (2016) 2198 – 2207
bortezomib-induced change. This suggested adaptive changes in
the reducing and protein-folding machinery of the ER.
Global quantitative protein expression in proteasome inhibitor-
adapted myeloma cells
We chose a proteomic approach to identify the full pattern of
proteins with signiﬁcant changes in the expression levels in
AMO-1 vs AMO-BTZ and AMO-CFZ cells. In each experiment,
43500 different proteins were identiﬁed, of which 42000
proteins showed consistent peptide identiﬁcation for both labels
and in each triplicate, and were thus used for quantiﬁcation,
resulting in 4600 protein species identiﬁed with statistically
signiﬁcant changes in the expression levels in proteasome
inhibitor-adapted cells, compared with the non-adapted controls
(three independent replicates, Po0.01, Table 2, Supplementary
Figure 1. Relationship between cytotoxicity and proteasome β-subunit activity. AMO-1 cells and its derivatives adapted to bortezomib
(AMO-BTZ) and carﬁlzomib (AMO-CFZ) have been cultured for 2 weeks without proteasome inhibitors. Then AMO-1, AMO-BTZ and AMO-CFZ
were treated for a 1-h pulse with different concentrations of (a) bortezomib (Btz) or (b) carﬁlzomib (Cfz). Proteasome activity after drug
exposure was measured directly using activity-speciﬁc, ﬂuorescent chemical probes.23 Cell viability was determined after cells were grown in
fresh medium for 48 h following the 1-h drug exposure. Panels represent (in the order from left to right): cell viability determined by MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) test, activity of the proteasome β5c/5i, β1c/1i and
β2c/2i subunits, respectively, as assessed by activity-based labeling, for each cell type (AMO-1, AMO-BTZ, AMO-CFZ, horizontal rows) and for
each proteasome inhibitor (bortezomib, carﬁlzomib, panels a and b). Data are presented as a mean± s.d. of three independent replicates.
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Figure S4). Interestingly, in the bortezomib-adapted leukemia cell
line HL60-BTZ, only 300 proteins showed signiﬁcantly changed
expression levels, although a similar total number of proteins was
identiﬁed and quantiﬁed as in the myeloma cell lines.
The differentially expressed proteins were subjected to a
protein–protein interaction search to build a protein–protein
interaction network (Supplementary Figure S5). This resulted in a
complex network of changes in proteasome inhibitor-adapted
cells. Differentially expressed proteins were therefore subjected to
a Gene Ontology (GO) analysis, resulting in an average of 30 GO
terms for the overexpressed proteins and 10 for the down-
regulated species in all the three adapted clones (Supplementary
Table S1). GO terms involving the ubiquitin proteasome pathway
were enriched in all samples, in agreement with proteasome
overexpression. GO terms were manually grouped into function-
ally related clusters resulting in 5–6 groups of differentially
expressed proteins (Table 2; see also Supplementary Tables S2–S7
for individual upregulated/downregulated proteins per GO
pathway). This supervised clustering showed some general
concordance between the adapted cells, suggesting that acquired
resistance to proteasome inhibitors is characterized by a complex,
but characteristic pattern, of changes in protein expression.
The quantitatively largest group with altered expression levels
was a group of proteins involved in metabolic regulation,
comprising close to 50% of all polypeptide species with
expression changes identiﬁed. This suggested that metabolic
homeostasis is a major challenge for myeloma cells adapted to
proteasome inhibitor treatment. Upregulated proteins included
proteins involved in the respiratory chain (for example, CYC1 or
UQCR1), the generation of metabolites (for example, BLVRA or
APOA1BP), glycolysis (for example, PFKP or PKM) and amino
acid (for example, GOT1 or EEFSEC) or nucleic acid metabolism
(for example, UMPS or BOP1). The metabolic regulation category
also contained proteins (30%) that were signiﬁcantly down-
regulated, in particular proteins involved in lipid and cofactor
metabolism (for example, ASCT2 or ACLY). Of the top 25
Figure 2. Protein and RNA expression for UPR signaling pathway. AMO-1 and its derivatives adapted to bortezomib (AMO-BTZ) and
carﬁlzomib (AMO-CFZ) have been cultured for 2 weeks without proteasome inhibitors before RNA and protein was collected. (a) Level of
spliced (s), unspliced (u) and total (t) XBP1 in the cell lines. (b) Presence of activated XBP1 depicted as a ratio of spliced XBP1 vs unspliced XBP1
in the cell lines. (c) Representative western blotting bands for protein levels of UPR signaling proteins in the cell lines. For panels a and b, data
are presented as mean± s.d. of three independent replicates. Statistical signiﬁcance o0.05 is marked by asterisks.
Table 1. IC50 values obtained for each β-subunit
Proteasome subunit AMO-1 AMO-BTZ AMO-CFZ
BTZ
IC50 (nM) (50% functional proteasome inhibition) β2c NA NA NA
β2i NA NA NA
β1c 40 60 50–60
β1i 20–25 50 50–60
β5c 25 80–90 50–60
β5i 30 80–90 50–60
LD50 (nM) (50% cell viability) 50 41000 41000
CFZ
IC50 (nM) (50% functional proteasome inhibition) β2c 300 220 41000
β2i 180 90 800
β1c 4500 600 41000
β1i 4250 250 1000
β5c 10 50 90
β5i 10 50 250
LD50 (nM) (50% cell viability) 150 41000 41000
IC50 values for the inhibition of proteasome β-subunits in AMO-1-sensitive cells and AMO cells adapted to bortezomib (AMO-BTZ) and carﬁlzomib (AMO-CFZ)
during treatment with bortezomib (Btz) and carﬁlzomib (Cfz), as deferred from subunit-selective activity-based ﬂuorescent labeling, in relation to the LD50
(50% cell viability, determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)). NA, not applicable or
41000 nM indicate no signiﬁcant effect on the IC50 value up to 1000 nM.
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Figure 3. Activation of the UPR-induced apoptotic machinery. AMO-1 derivatives adapted to bortezomib (AMO-BTZ) and carﬁlzomib
(AMO-CFZ) have been cultured for 2 weeks without proteasome inhibitors. Then, together with AMO-1 sensitive cell line, they were treated
with 500 nM bortezomib for a 1-h pulse. After the pulse, cells were grown in fresh medium for different chase time points (0.5, 1, 2, 4, 8, 16,
24 h). Directly before the addition of the proteasome inhibitor (presample) and immediately after the pulse (postsample), as well as at each
chase time point indicated, an aliquot was harvested for protein isolation, and equal amounts of protein from each sample were subsequently
processed for western blotting. Data are presented as representative bands of three independent experiments.
Table 2. Proteomic comparison of AMO-1 cells with AMO-BTZ and AMO-CFZ
Change GO term P-value range Number of proteins Mean fold change (range)
AMO-BTZ
Upregulated Protein catabolism 10− 8 19 1.7 (2.3–1.4)
Redox homeostasis 10− 7–10− 6 25 1.9 (6.1–1.4)
Folding and complex formation 10− 3–10− 2 53 2.0 (19.7–1.4)
Transport/signaling 10− 3–10− 2 116 1.7 (4.3–1.4)
Metabolic regulation 10− 3–10− 2 114 1.8 (9.2–1.4)
Downregulated Transcription/translation 10− 2 63 0.6 (0.7–0.2)
Differentiation 10− 2 13 0.6 (0.7–0.4)
Cytoskeleton organization 10− 2 22 0.5 (0.7–0.1)
Metabolic regulation 10− 2 45 0.6 (0.7–0.4)
Transport/signaling 10− 2 89 0.5 (0.7–0.1)
Apoptosis 10− 1 8 0.5 (0.7–0.3)
AMO-CFZ
Upregulated Protein catabolism 10− 8 22 1.7 (2.7–1.4)
Transport/signaling 10− 6–10− 2 85 1.9 (12.1–1.4)
Metabolic regulation 10− 6–10− 2 110 1.8 (4.6–1.4)
Folding and complex formation 10− 3–10− 2 39 2.2 (13.9–1.4)
Redox homeostasis 10− 3–10− 2 15 2.2 (4.3–1.4)
Downregulated Apoptosis 10− 3 7 0.5 (0.7–0.2)
Metabolic regulation 10− 3–10− 2 58 0.5 (0.7–0.2)
Transport/signaling 10− 2 72 0.5 (0.7–0.1)
Transcription/translation 10− 2 58 0.6 (0.7–0.2)
Differentiation 10− 2 10 0.5 (0.7–0.2)
Cytoskeleton organization 10− 2 24 0.5 (0.7–0.1)
HL60–BTZ
Upregulated Protein catabolism 10− 15 23 1.7 (2.7–1.4)
Transport/signaling 10− 10–10− 2 80 1.8 (6.8–1.4)
Metabolic regulation 10− 3–10− 2 65 1.8 (4.5–1.4)
Folding and complex formation 10− 2 28 1.8 (3.9–1.4)
Redox homeostasis 10− 2 20 1.9 (4.4–1.4)
Downregulated Transport/signaling 10− 5 40 0.6 (0.7–0.3)
Metabolic regulation 10− 3–10− 2 34 0.6 (0.7–0.3)
Transcription/translation 10− 2 64 0.6 (0.7–0.2)
Redox homeostasis 10− 2 16 0.6 (0.7–0.2)
Cytoskeleton organization 10− 2 12 0.6 (0.7–0.4)
Abbreviation: GO, gene ontology. Supervised clustering of GO terms into functionally related clusters of biological processes found for the upregulated and
downregulated proteins in the cell lines adapted to bortezomib (AMO-BTZ, HL60-BTZ) and carﬁlzomib (AMO-CFZ). P-values range is obtained from the
unsupervised clusters of different GO terms (see Supplementary Table S1) clustered in each category.
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quantitatively downregulated proteins in this cluster, 12 were
mitochondrial proteins involved in fatty acid biosynthesis (ACSF2,
ACSF3) in AMO-CFZ, and likewise ﬁve mitochondrial proteins
with similar function were among the top 25 downregulated in
AMO-BTZ. Proteins involved in protein catabolism, redox control
and protein folding were also overexpressed. This included all
proteasome alpha (PSMA 1,2,3,4&7) and beta (PSMB 1,2,3,4,5&7)
subunits and corroborated the validity of our analysis. Proteins
involved in antioxidant and reactive oxygen species functions
(NQO1, PRDX1, SOD1) were also increased in adapted cells, as well
as proteins involved in glutathione regulation. Different individual
proteins were upregulated in a given functional pathway between
AMO-BTZ and AMO-CFZ (for example, GPX1, one of the major
enzymes responsible for glutathione peroxidation and thus
removal of oxygen peroxide, was only overexpressed in AMO-
BTZ, but not in AMO-CFZ, while glutathione transferase 1 (MGST1),
which acts by conjugating reduced glutathione to a wide number
of exogenous and endogenous hydrophobic electrophiles, was
only found upregulated in AMO-CFZ, of which a variant (MGST3)
was found upregulated in AMO-BTZ). However, the upregulation
of proteins involved in redox pathways overall showed a very
consistent pattern between AMO-CFZ and AMO-BTZ cells. Of the
16 proteins signiﬁcantly upregulated in this cluster in AMO-CFZ
cells, 12 were likewise found upregulated in AMO-BTZ cells,
suggesting a central role of the redox equilibrium. The protein
folding/chaperoning capacity of the adapted cells was also
markedly increased: the heat-shock proteins HSP70, HSP90 and
HSP105 were consistently among the top 15 most strongly
upregulated proteins (2.3–13-fold increase) among proteins
involved in folding/chaperoning in both adapted cell clones.
A pattern of downregulation was observed for protein clusters
involved in transcription/translation, differentiation, apoptosis
and structural/cytoskeletal functions. Transcription and translation
regulation proteins comprised about one-fourth of the total
downregulated protein species. The apoptosis protein cluster
comprised the lowest number of proteins, of which both adapted
cells markedly downregulated individual key proteins (decreased
BAX in AMO-CFZ, decreased CASP10 and DIABLO in AMO-BTZ).
Downmodulation of cytoskeleton and cell differentiation included
IKZF3, a transcription factor implicated in lymphocyte differentia-
tion and activity of immunomodulatory myeloma drugs. AMO-BTZ
cells were signiﬁcantly more sensitive to lenalidomide, consistent
with a role of IKZF3 levels, while AMO-CFZ were lenalidomide
refractory, potentially explained by their high ABCB1 expression
(Supplementary Figure S6A).
Upregulation of MDR1 and oxidative glycolysis functionally
contribute to resistance
ABCB1, the MDR1, was 12-fold upregulated only in AMO-CFZ on
the protein and 120-fold by gene expression analysis (data not
shown). Likewise, we observed 4100 × increased ABCB1 gene
expression in carﬁlzomib-adapted ARH-77 plasma cell leukemia
cells (ARH-CFZ) and primary malignant plasma cell samples from a
myeloma patient who initially responded to carﬁlzomib treatment
and later showed progressive disease under carﬁlzomib. The
primary patient sample showed more than four-fold upregulated
ABCB1 expression upon progression, compared with the baseline
(Supplementary Figure S7). The addition of the functional MDR1
inhibitors verapamil and reserpine signiﬁcantly decreased the
LD50 for CFZ-treated AMO-CFZ cells, in contrast to AMO-BTZ cells
or AMO-CFZ cells treated with bortezomib, suggesting a high
functional signiﬁcance of ABCB1 overexpression for CFZ resistance
(Figure 4 and Supplementary Figure S8). The sensitivity of AMO-
CFZ against cyclophosphamide or daunorubicin was unchanged
(Supplementary Figures S6C and D), while AMO-BTZ and AMO-CFZ
showed decreased sensitivity for panobinostat, consistent with
the role of HDAC6 in non-proteasomal protein degradation
(Supplementary Figure S6B).
Oxidative glycolysis is upregulated in proteasome inhibitor-
resistant myeloma cells
NADPH dehydrogenase, the quantitatively most important oxidor-
eductase in eukaryotic cells, was overexpressed 4–6-fold in AMO-
BTZ and AMO-CFZ, respectively, and in addition the enzymes that
generate NADPH (malate dehydrogenase and enzymes of the
oxidative branch of the pentose phosphate pathway (PPP)) were
found overexpressed, implicating that increased production of
Figure 4. Cytotoxic effect of speciﬁc ABCB1 inhibitor verapamil. The AMO-1 cell line and its derivatives adapted to bortezomib (AMO-BTZ) and
carﬁlzomib (AMO-CFZ) have been cultured in the presence of 5 μM verapamil and bortezomib/carﬁlzomib (Btz/Cfz) for 5 days and viability was
assessed by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) test. Absorbance values of
treated cells were normalized to the controls without speciﬁc inhibitors. Data are presented as a mean± s.d. of three independent replicates.
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reducing equivalents may serve as a metabolic adaptive response
to render cells more proteasome inhibition resistant. Glycolysis
can contribute signiﬁcantly to the synthesis of reducing equiva-
lents via NAPDH (via PPP and mitochondrial pyruvate–malate
cycle) and NADH (glycolysis and TCA cycle), which are crucial
for maintenance of redox balance and neutralization of reactive
oxygen species. Indeed, we observed that the AMO-BTZ and
AMO-CFZ cells displayed higher baseline and maximum glycolytic
rates than their parental cell line (Figure 5a) as determined
by real-time metabolic ﬂux analysis, a ﬁnding that is supported
by the increased expression of several glycolytic enzymes
(Supplementary Tables S2 and S4). Consistent with these ﬁndings,
high glucose medium decreases the proteasome inhibitor
sensitivity of AMO-1 cells, in contrast to AMO-CFZ or AMO-BTZ
(Supplementary Figure S9). Malignant cells often display increased
glycolytic rates with lactate as end product despite the availability
of ample oxygen (Warburg Effect), a phenomenon thought to
reﬂect a metabolic adaptation to maintain cellular ATP levels in
the face of often dysfunctional mitochondria. In agreement with
the increased expression of several proteins of the electron
transport chain in AMO-BTZ and AMO-CFZ cells (Supplementary
Tables S2 and S4), we found, however, that these cells showed
higher baseline and maximum mitochondrial respiration than the
AMO-1 cell line (Figure 5b), indicative of enhanced mitochondrial
activity and health. This suggests that the enhanced glycolytic ﬂux
in these cells is unlikely merely a bioenergetic adaptation to
impaired ox-phos but may have a role in fueling the PPP and TCA
to, among other things, aid in the generation of reducing
equivalents. To further test this concept, we used FX11, a speciﬁc
inhibitor of lactate dehydrogenase A that catalyzes the conversion
of pyruvate into lactate (Figure 5c), thereby instead promoting the
oxidation of pyruvate in the mitochondria. Indeed, this selective
block of aerobic glycolysis considerably increased the LD50 for
bortezomib in AMO-1, AMO-BTZ and AMO-CFZ cells. This would
be in support of the notion that the increased glycolysis in
AMO-BTZ and AMO-CFZ cells is not ATP-driven but may rather
serve to fuel mitochondrial metabolism and the PPP that could
help in the generation of reducing power to mitigate the
deleterious effects of proteasome inhibition.
DISCUSSION
Proteasome PSMB5 gene mutations are believed to explain clinical
proteasome inhibitor resistance, although attempts have failed to
identify them in patient-derived material. This 'mutation model'
was challenged when downmodulation of IRE1/sXBP1 was shown
to result in proteasome inhibitor resistance while 'IRE1/XBP1-low'
myeloma cells accumulate in bortezomib-resistant patients.
We demonstrate that proteasome inhibitor-adapted myeloma
cells tolerate near-complete inhibition of proteasome activity,
irrespective of the presence of a PSMB5 mutation. Furthermore,
AMO-BTZ and AMO-CFZ showed an 'IRE1/XBP1-low' pattern of
UPR activation, independently from proteasome mutations. These
data argue against individual PSMB5 mutations as key factor for
Figure 5. Role of glycolysis in proteasome inhibitor resistance. (a, b) The AMO-1 cell line and its derivatives adapted to bortezomib (AMO-BTZ)
and carﬁlzomib (AMO-CFZ) were seeded in a 96-well XF Extracellular Flux Analyzer to simultaneously quantify (a) extracellular acidiﬁcation
rates (ECAR) and (b) oxygen consumption rates (OCR) as measures of glycolysis and mitochondrial respiration, respectively. (a) Real-time
baseline glycolytic rate of the different cell lines was determined by subtracting the difference in levels in ECAR before and after injection of
10 mM glucose. Reserve glycolytic capacity was calculated by subtracting baseline ECAR readings from ECAR values following treatment with
ETC blockers antimycin A/rotenone. (b) Real-time OCR was determined during sequential treatments with oligomycin (ATP-synthase inhibitor),
FCCP (uncoupler) and antimycin-A/rotenone (ETC inhibitors). Maximum mitochondrial respiration is reached following treatment with FCCP
that leads to uncoupling of the mitochondria. Data represent means± s.e.m. of eight replicates. One representative experiment of three is
shown. (c) The AMO-1 cell line and its derivatives adapted to bortezomib (AMO-BTZ) and carﬁlzomib (AMO-CFZ) have been cultured in
the presence of 40 μM FX11, and bortezomib (Btz) for 5 days, and viability was assessed by MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) test. Absorbance values of treated cells were normalized to the controls without
speciﬁc inhibitors. Data are presented as a mean± s.d. of three independent replicates.
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proteasome inhibitor resistance and support the 'IRE1/XBP1-low'
model. They also suggest that proteasomal proteolysis is no
longer the 'Achilles’ heel' of proteasome inhibitor-resistant
myeloma but that its functionality is almost dispensable.
Because our ﬁndings suggested a complex biology of protea-
some inhibitor resistance, we undertook the ﬁrst quantitative
proteome analysis of proteasome inhibitor-resistant myeloma. Our
results show that adaptation of myeloma to proteasome inhibitors
involves complex changes in hundreds of proteins. The gross
pattern observed was similar between AMO-BTZ and AMO-CFZ
cells and may be understood as characteristic adaptive response
to proteasome inhibition, balancing the equilibrium between
proteasomal load and capacity at a new functional level of very
low proteasome activity. Although different proteins were
involved in the adaptation process between both cell lines, the
pattern of changes in particular included proteins involved in
energy homeostasis or the production, folding or destruction of
protein. Our data are consistent with the observation that
proteasome overexpression mediated by nuclear factor 2 (NRF2)
can contribute to adaptive resistance to proteasome inhibitors,27
although in our model NRF2 was not upregulated (data not
shown).
To our knowledge, while all bortezomib-adapted myeloma
cells with a biologically meaningful resistance factor 45 × that
tolerate high (100 nM) bortezomib concentrations contain a PSMB5
mutation,28 carﬁlzomib-resistant myeloma cells have not yet been
Figure 6. Model of redox homeostasis and metabolic changes during the adaptation to proteasome inhibitors. Excessive proteotoxic stress is
the major mechanism of cytotoxicity of proteasome inhibitors in myeloma. The level of proteotoxic stress results from the degree of
imbalance between proteasomal load and proteasomal proteolytic capacity. The proteasomal load of misfolded protein is tightly connected
to the protein-folding capacity of the ER, which in turn relies on proper redox conditions. NAD(P)H is critical for providing oxidizing
equivalents and thus for minimizing the proteasomal load in proteasome inhibitor-adapted myeloma cells that are viable with extremely low
proteasome activity while producing high paraprotein amounts. NAD(P)H is mostly provided from intermediates of the TCA (Krebs Cycle), for
example, malate–pyruvate and mitochondrial isocitrate dehydrogenase reactions, which we found consistently upregulated in proteasome
inhibitor-adapted myeloma cells. In line with this, multiple other enzymes that are involved in NAD(P)H generation were upregulated, while
enzymes mediating lipid biosynthesis from Acetyl-CoA, which removes tricarboxylic acid intermediates from the Krebs Cycle and thus
decreases NAD(P)H generation, are downregulated. This way, we hypothesize that maximum NAD(P)H-producing intermediates may be
provided, limiting proteotoxic stress in adapted/resistant cells. Cancer cells often use the faster, but less efﬁcient, pathway for ATP production
to generate ATP via pyruvate–lactate conversion (Warburg effect). When this is inhibited using the speciﬁc inhibitor of LDHA, FX-11, the
sensitivity of myeloma cells to proteasome inhibitors decreases, presumably because glucose metabolism entirely switches to the TCA cycle,
increasing NAD(P)H production and reducing proteotoxic stress. Upregulation of ABCB1 decreases proteotoxic stress via reduced intracellular
concentrations of proteasome inhibitors, which can be reversed by speciﬁc ABCB1 inhibitors Verapamil or Reserpine. ABCB1, ATP-binding
cassette, sub-family B (MDR/TAP) member 1; ACLY, ATP Citrate Lyase; ACSF2, Acyl-CoA synthetase family member 2; ACSF3, Acyl-CoA
synthetase family member 3; ARE, antioxidant response elements; BVLRA, biliverdin reductase; CoQ, coenzyme Q; CoQH2, coenzyme
Q-reduced; CytC, cytochrome C; GSSG, oxidized glutathione; GSH, reduced glutathione; GOT1, glutamic-oxaloacetic transaminase 1; GPX,
glutathione peroxidase; LDHA, lactate dehydrogenase; NQO1, NAD[P]H dehydrogenase, quinone1; NRF2, nuclear factor (erythroid-derived 2)-
like 2; PDI, protein disulﬁde isomerase; PEP, phosphoenolpyruvate; PI, proteasome inhibitors; PKM, pyruvate kinase, muscle; PRDX,
peroxiredoxin; ROS, reactive oxygen species; SOD, superoxide dismutase; UQ, ubiquinone.
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reported. AMO-CFZ cells described here lack a mutation in the
PSMB5, PSMB6 or PSMB7 genes, have a resistance factor of
approximately 420 × and 47 × for carﬁlzomib and bortezomib,
respectively, and tolerate very high concentrations of each of the
proteasome-inhibiting drugs, so that they represent the ﬁrst
comprehensive cell line model for proteasome inhibitor resistance
and at the same time mirror the mutation status as well as the
'IRE1/XBP1-low' biology found in resistant patients. The A310G
mutation at Met45Val directly affects the S1-binding pocket in the
β5 substrate channel and signiﬁcantly impairs chymotryptic
proteasome activity and binding to bortezomib or carﬁlzomib.17
We demonstrate that the heterozygous Met45Val mutation results
in 3–5-fold lower β5-inhibiting activity of bortezomib and
carﬁlzomib in human myeloma cells.
The MDR ABCB1 was the most signiﬁcantly upregulated protein
in AMO-CFZ cells. MDR-mediated resistance to carﬁlzomib has
been observed in solid tumor cells,29 in contrast to bortezomib,
and we did not observe ABCB1 upregulation in AMO-BTZ cells.
The increased IC50 for inhibition of all individual proteasome
subunits in AMO-CFZ cells after carﬁlzomib treatment is consistent
with drug export. Indeed, co-treatment of AMO-CFZ with
carﬁlzomib and MDR inhibitors decreased carﬁlzomib resistance.
Given the redundancy of signaling and the genetic architecture
of advanced myeloma, targeting individual signaling proteins
may lack signiﬁcant activity in proteasome inhibitor-refractory
myeloma. However, most of these patients still have measurable
paraprotein levels, indicating that bortezomib-adapted myeloma
cells in vivo usually continue to produce high amounts of secretory
protein. Our results suggest that such myeloma cells may secure
continued paraprotein production by entertaining a highly
optimized machinery of protein folding via increased chaperone
expression and stringent redox conditions, thus minimizing
defective folding that would otherwise increase proteasomal load.
Indeed, AMO-CFZ maintained fully functional IgA secretion levels,
whereas paraprotein secretion was absent from AMO-BTZ
(Supplementary Figure S10). Adequate supply of energy and
oxidizing equivalents are key requisites toward proper redox
conditions. Tumor cells often use aerobe glycolysis instead of
oxidative generation of ATP, called 'Warburg Effect'. However, the
oxidative glucose turnover is also one of the major providers of
NADPH, the most important oxidizing agent, regenerated from
NADP when malate from the Krebs cycle is converted into
pyruvate. Indeed, several of our results suggest that the
metabolism of proteasome inhibitor-resistant myeloma cells has
been geared to provide NADPH for reducing activity with high
efﬁciency: NADPH dehydrogenase, the most important oxidor-
eductase in eukaryotes was overexpressed 4–6-fold in AMO-BTZ
and AMO-CFZ cells, similarly to malate dehydrogenase and
enzymes of the PPP, the most important providers of NADPH.
At the same time, several enzymes involved in synthesis of fatty
acids and lipids from pyruvate/citrate backbones in the mitochon-
dria via Acetyl-CoA were among the top downregulated proteins
in both AMO-CFZ and AMO-BTZ cells, so that mitochondrial
pyruvate is, to a smaller fraction, used as building blocks for lipid
biosynthesis and can, to a larger fraction, undergo oxidative
glycolysis. These characteristics suggest a quantitative adaptation
in the ﬂow of metabolic intermediates in proteasome inhibitor-
resistant myeloma cells, optimizing for the provision of energy
and oxidizing equivalents via oxidative glycolysis (see proposed
metabolic model of proteasome inhibitor-adapted myeloma cells,
Figure 6). Proteasome inhibitor-resistant myeloma may thus be
sensitive to the manipulation key metabolic processes, that is,
oxidation of glucose, or the generation of NADPH and/or ATP.
A comparison of the metabolomes between AMO-1, AMO-BTZ and
AMO-CFZ is currently underway.
We document that proteasome activity is largely dispensable
in bortezomib- or carﬁlzomib-adapted myeloma cells, suggesting
that nonproteasomal targets are required to overcome
proteasome inhibitor resistance. PSMB5 mutations are likewise
not required for high-level proteasome inhibitor resistance of
myeloma, while an important role of the 'IRE1/XBP1-low'
activation status of the UPR is supported. Our full proteomic
analysis of proteasome inhibitor-resistant myeloma cells reveals a
complex adaptation pattern that in particular involves changes in
glycolysis, protein folding and redox function. Our data suggest
exploring these metabolic pathways in proteasome inhibitor-
resistant myeloma.
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